Table 2

Agents used for treatment of recurrent low-grade serous carcinoma with prospective data available

AgentStudyResponse rate
Liposomal doxorubicinGOG-0281/LOGS and MILO/ENGOT-ov113% (1/40); 14% (9/66)
TopotecanGOG-0281/LOGS and MILO/ENGOT-ov110% (0/8); 0% (0/9)
Weekly paclitaxelGOG-0281/LOGS and MILO/ENGOT-ov119% (1/11); 15% (4/26)
TamoxifenGOG-0281/LOGS0% (0/27)
LetrozoleGOG-0281/LOGS14% (6/44)
TrametinibGOG-0281/LOGS26% (34/130)
BinimetinibMILO/ENGOT-ov1116% (32/198)